5PSQ-026 Efficacy and safety of evolocumab in hypercholesterolaemia and mixed dyslipidaemia

BACKGROUND: The main goal in the therapy of lipids disorders is to prevent morbidity associated with cardiovascular mortality. Evolocumab is a new drug appropiate in reducing the cholesterol level in hypercholesterolaemia and mixed dyslipidaemia. PURPOSE: To describe the efficacy and safety of evolo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Hosp Pharm
Hlavní autoři: Díez, B Cancela, Muñoz, C, Claramunt, R, Guijarro, S, Barbero, MJ, Horno, F
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2018
Témata:
Section 5: Patient safety and quality assurance
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535229/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.380
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky